Questcor weakness a buying opportunity, says Mizuho Mizuho said Questcor weakness related to another Citron Research questioning the composition of Acthar based on its own testing is a buying opportunity. The analyst believes there was a label error in testing and that any FDA analysis will come to the same conclusion. Shares are Buy rated with a $93 price target.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.
Mallinckrodt price target lowered to $77 from $90 at Leerink Leerink lowered its price target for Mallinckrodt (MNK) shares to $77 citing a heightened risk profile from the Questcor (QCOR) acquisition and significant earnings concentration in Acthar. The firm says it remains on the sidelines with a Market Perform rating on Mallinckrodt.
Mallinckrodt remains favorite specialty pharmaceutical name, says UBS UBS said Mallinckrodt (MNK) remains its favorite specialty pharmaceutical name following the company's update on its merger with Questcor (QCOR). The firm sees estimates increasing following the close of the transaction, the divestiture of the Medical Imaging division, and the reinvestment in higher margin assets. UBS has a Buy rating with a $94 price target on Mallinckrodt.